MaxCyte Partners with Prime Medicine to Advance Gene Editing Therapies

MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, de...

August 02, 2023 | Wednesday | News
Melinta Therapeutics Announces Commercial Availability of REZZAYO™ (rezafungin for injection)

Melinta Therapeutics, LLC  announced the availability of REZZAYO™ (rezafungin for injection), for the treatment of candidemia and invasive candi...

August 01, 2023 | Tuesday | News
IDTechEx Examines the Role of Antimicrobial Technology in Combating Healthcare Infections.

Each year, millions of patients contract infectious diseases while in hospital. These HAIs not only lengthen hospital stays and utilize resources, such as ...

July 31, 2023 | Monday | News
EmVenio Research & TrialHub Partner to Boost Clinical Trial Efficiency

Through TrialHub's data intelligence gathering platform, EmVenio can easily identify optimal markets to attract clinical trial participants who are needed ...

July 28, 2023 | Friday | News
Autophagy Signaling Pathways: Therapeutic Targets for Neurodegenerative Diseases

A hallmark of many neurodegenerative disorders is the accumulation of damaged or abnormally folded proteins. The impact of such intracellular accumulations...

July 27, 2023 | Thursday | Analysis
Teva Pharmaceuticals and Alvotech Share Update on Biosimilars Partnership

The partners continue working closely on matters concerning pending approval in the U.S. for AVT02, an interchangeable high-concentration biosimilar candid...

July 25, 2023 | Tuesday | News
ImmunoGen Partners with ImmunoBiochem for Next-Gen Antibody-Drug Conjugates

Collaboration Combines ImmunoGen's Proprietary Linker-Payload Technology with Antibodies Developed by ImmunoBiochem Agreement Grants ImmunoGen an Exclusiv...

July 25, 2023 | Tuesday | News
Biocon Biologics Announces Positive CHMP Opinion for YESAFILI®, Biosimilar Aflibercept

The CHMP positive opinion will be considered by the European Commission. The European Commission decision on the approval is expected by the end of Se...

July 24, 2023 | Monday | News
Gilead To Discontinue Phase 3 ENHANCE Study of Magrolimab Plus Azacitidine in Higher-Risk MDS

Magrolimab is a potential first-in-class, anti-CD47 immunotherapy with a clinical development program spanning ten potential indications including ongoing ...

July 24, 2023 | Monday | News
Tillotts Pharma and TVM Capital Form Mage Biologics to Develop Oral Antibody Therapy for Ulcerative Colitis

Novel antibody specifically designed for oral administration utilizes Tillotts Pharma’s sustained release approach to ensure optimal and local trea...

July 21, 2023 | Friday | News
PromoCell Launches PromoExQ MSC Growth Medium XF for GMP-Compliant MSC Expansion

PromoExQ MSC Growth Medium XF enables the long-term expansion of a variety of MSC types, including MSCs from the bone marrow, umbilical cord matrix, and ad...

July 21, 2023 | Friday | News
HUTCHMED's Fruquintinib Combo Receives Breakthrough Designation in China for Advanced Endometrial Cancer, Enrollment Complete

It is a multi-center, open-label clinical study to evaluate the efficacy and safety of fruquintinib in combination with sintilimab. Entry criteria include ...

July 20, 2023 | Thursday | News
Yikaida CAR-T Cell Therapy Approved as a Second-line Therapy for New Indication

Previously, there was no CAR-T cell therapy product in China for the treatment of adult large B-cell lymphoma who failed to respond to first-line immunoche...

July 19, 2023 | Wednesday | News
Eleven Therapeutics Collaborates with Novo Nordisk for Nucleic Acid Therapeutics Discovery

 Through this collaboration, the companies aim to identify novel molecules that promote precise delivery of nucleic acid by leveraging Eleven's innova...

July 18, 2023 | Tuesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close